NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury

Starting soon · Not applicable · Has a placebo group

Conditions studied: Acute Kidney Injury

In brief

The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.

Key facts

Study ID: NCT07739290
Run by: Beth Israel Deaconess Medical Center
People needed: 20
Starts: 2026-09-01
Expected to finish: 2029-01-01
Last updated by the study team: 2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18 years
Undergoing coronary artery bypass graft (CABG) and/or valve surgery with cardiopulmonary bypass (CPB) at BIDMC. Includes combination surgeries that involve CABG and/or valve plus other procedures (e.g., Maze procedure, aortic aneurysm repair).
AKI risk score ≥6 at the time of screening

You may not qualify if…

History of AKI in the seven days prior to surgery, defined as any of the following:
Increase in serum creatinine ≥0.3 mg/dl in 48h
Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use most recent value in last 3 months)
Urine output ≤0.5 ml/kg/h x 6 consecutive hours (only assessed in patients with hourly monitoring via Foley catheter)
Receipt of renal replacement therapy (RRT) within 7d
Advanced chronic kidney disease (eGFR <15 ml/min/1.73m2 or end-stage kidney disease receiving RRT)
Pregnant or breastfeeding*
Positive COVID test in the last 10 days.
Prisoner or institutionalized
Existing or anticipated durable VAD
Conflict with other studies
Previous usage of nicotinamide supplements in the past 30 days

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.